{"organizations": [], "uuid": "487d5cf59fbf3f488fc0acb467102fde4331ddad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/samsung-biologic-accounting/samsung-biologics-said-jv-partner-biogen-to-exercise-option-by-late-june-idUSL3N1SO5XH", "country": "US", "domain_rank": 408, "title": "Samsung BioLogics said JV partner Biogen to exercise option by late June", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-18T01:46:00.000+03:00", "replies_count": 0, "uuid": "487d5cf59fbf3f488fc0acb467102fde4331ddad"}, "author": "", "url": "https://www.reuters.com/article/samsung-biologic-accounting/samsung-biologics-said-jv-partner-biogen-to-exercise-option-by-late-june-idUSL3N1SO5XH", "ord_in_thread": 0, "title": "Samsung BioLogics said JV partner Biogen to exercise option by late June", "locations": [], "entities": {"persons": [{"name": "joori roh", "sentiment": "none"}, {"name": "grant mccool", "sentiment": "none"}], "locations": [{"name": "seoul", "sentiment": "none"}], "organizations": [{"name": "samsung biologics", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "samsung bioepis", "sentiment": "none"}, {"name": "biologics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SEOUL, May 18 (Reuters) - Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.\nBiogen sent a letter to the South Korean biotech drug maker that it planned to use the option by June 29, BioLogics said in a regulatory filing. (Reporting by Ju-min Park and Joori Roh; Editing by Grant McCool)\n ", "external_links": [], "published": "2018-05-18T01:46:00.000+03:00", "crawled": "2018-05-18T02:06:02.006+03:00", "highlightTitle": ""}